The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4308-4313

  MacGregor Schafer, Jennifer I ^a   Liu, Hong ^a   Tonetti, Debra A ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ANTIESTROGEN; DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA; RALOXIFENE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PREVENTION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0344931629     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. MacGregor, J. I., and Jordan, V. C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev., 50: 151-196, 1998.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 351: 1451-1467, 1998.
3. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant breast and Bowel Project P-1 Study. J. Natl. Cancer Inst., 90: 1371-1388, 1998.
4. Gradishar, W. J., and Jordan, V. C. The clinical potential of new antiestrogens. J. Clin. Oncol., 15: 480-489, 1997.
5. Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., and De Mets, D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med., 326: 852-856, 1992.
6. Black, L. J., Jones, C. D., and Falcone, J. F. Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sci., 32: 1031-1036, 1983.
7. Delmas, P. D., Bjamason, N. H., Mitlak, B. H., Ravoux, A-C., Shah, A. S., Huster, W. J., Draper, M., and Christiansen, C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med., 337: 1641-1647, 1997.
8. Jordan, V. C. Molecular mechanism of action of raloxifene and tamoxifen: today and tomorrow. J. Natl. Cancer Inst., 90: 967-971, 1998.
9. Cummings, S. R., Eckert, S., Grady, D., Krueger, K. A., Glusman, J. E., Cauley, R., Powles, T. J., Norton, L., Nickelson, T., Morrow, M., Bjamason, N. H., Black, D., Costa, A., Lippman, M. E., and Jordan, V. C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J. Am. Med. Assoc., 281: 2189-2197, 1999.
10. Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J-A., and Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond. ), 389: 753-758, 1997.
11. Wolf, D. M., and Jordan, V. C. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. Treat., 31: 117-127, 1994.
12. Wolf, D. M., and Jordan, V. C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat., 31: 129-138, 1994.
13. Catherino, W. H., Wolf, D. M., and Jordan, V. C. A naturally occurring estrogen receptor mutation results in increased estrogenicity for a tamoxifen analog. Mol. Endocrinol., 9: 1053-1063, 1995.
14. Levenson, A. S., Tonetti D. A., and Jordan, V. C. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor α mRNA in MDAMB-231 breast cancer cells stably expressing the oestrogen receptor. Br. J. Cancer, 77: 1812-1819, 1998.
15. Levenson, A. S., Catherino, W. H., and Jordan, V. C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol., 60: 261-268, 1997.
16. Levenson, A. S., and Jordan, V. C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (Asp) in the estrogen receptor. Cancer Res., 58: 1872-1875, 1998.
17. Gauthier, S., Caron, B., Cloutier, J., Dory, Y. L., Farve, A., Larouche, D., Mailhot, J., Ouelett, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., and Labrie F. (S)-(+)-[4-[7-(2,2-Dimethyl-l-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active nonsteroidal antiestrogen. J. Med. Chem., 40: 2117-2122, 1997.
18. Martel, C., Provencher, L., Li, X., St. Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., and Labrie, F. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205, 1998.
19. Terenius, L. Structure-activity relationships of antioestrogens with regard to interaction with 17β-oestradiol in the mouse uterus and vagina. Acta Endocrinol., 66 (Suppl.): 431-447, 1971.
20. Jordan, V. C., Dix, C. J., Naylor, K. E., Prestwich, G., and Rowsby, L. Non-steroidal antioestrogens: their biological effects and potential mechanisms of action. J. Toxicol. Environ. Health, 4: 364-390, 1978.
21. Harper, M. J. K., and Walpole, A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil., 13: 101-119, 1967.
22. Jordan, V. C., Collins, M. M., Rowsby, L., and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent anti-oestrogenic activity. J. Endocrinol., 75: 305-316, 1977.
23. Bowler, J., Lilley, T. J., Pittman, J. D., and Wakeling, A. E. Novel steroidal pure antiestrogens. Steroids, 54: 71-99, 1989.
24. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
25. Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., and Nicholson, R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst., 87: 746-750, 1995.
26. Howell, A., DeFriend, D. J., Robertson, J. F. R., Blarney, R. W., Anderson, L., Anderson, E., Sutcliffe, F. A., and Walton, P. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with breast cancer. Br. J. Cancer, 74: 300-308, 1996.
27. Gibson, M. K., Nemmers, L. A., Beckman, W. C., Davis, V. L., Curtis, S. W., and Korach, K. S. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology, 129: 2000-2010, 1991.
28. Dauvois, S., Danielian, P. S., White, R., and Parker, M. G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor by increasing its turnover. Proc. Natl. Acad. Sci. USA, 89: 4037-4041, 1992.
29. Jiang, S-Y., and Jordan, V. C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst., 84: 580-591, 1992.
30. Green, S., Issemann, I., and Sheer, E. A versatile in vivo and in vitro eukaryotic vector for protein engineering. Nucleic Acids Res., 16: 369, 1988.
31. La Barca, C., and Paigen, K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem., 102: 344-352, 1980.
32. Pink, J. J., and Jordan, V. C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res., 56: 2321-2330, 1996.
33. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S. M., Mérand, Y., and Labrie, F. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112, 1997.
34. Dauvois, S., White, R., and Parker, M. G. The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci., 106: 1377-1388, 1993.
35. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95: 927-937, 1998.
36. Berry, M. M., Metzger, D., and Chambon, P. Role of the two activating domains in the estrogen receptor in the cell type and promoter context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen. EMBO J., 9: 2811-2818, 1990.
37. Horwitz, K. B., Jackson, T. A., Bain, D. L, Richer, J. K., Takimoto, G. S., and Tung, L. Nuclear receptor coativators and corepressors. Mol. Endocrinol., 10: 1167-1177, 1996.
38. Grese, T. A., Sluka, J. P., Bryant, H. U., Cullinan, G. J., Glasebrook, A. L., Jones, C. D., Matsumoto, K., Palkowitz, A. D., Sato, M., Termine, J. D., Winter, M. A., Yang, N. N., and Dodge, J. A. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. USA, 94: 14105-14110, 1997.